Page last updated: 2024-08-24

gemcitabine and pf 00299804

gemcitabine has been researched along with pf 00299804 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, AR; Nam, HJ; Oh, DY; Song, SH; Yoon, YK	1
Day, KC; Day, ML; Grivas, PD; Hussain, M; Karatsinides, A; Kunju, LP; Liebert, M; Owainati, I; Paul, A; Shakir, N; Thomas, D	1

Other Studies

2 other study(ies) available for gemcitabine and pf 00299804

Article	Year
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Investigational new drugs, 2012, Volume: 30, Issue:6 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Receptors, Growth Factor; STAT3 Transcription Factor	2012
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Molecular medicine (Cambridge, Mass.), 2013, Nov-08, Volume: 19 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolinones; Random Allocation; Receptor, ErbB-2; Receptor, ErbB-4; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2013

Article

Year

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.

Investigational new drugs, 2012, Volume: 30, Issue:6

Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Receptors, Growth Factor; STAT3 Transcription Factor

2012

Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.

Molecular medicine (Cambridge, Mass.), 2013, Nov-08, Volume: 19

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolinones; Random Allocation; Receptor, ErbB-2; Receptor, ErbB-4; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2013